

Case report

<https://doi.org/10.6065/apem.2040042.021>
Ann Pediatr Endocrinol Metab 2021;26:60-65



Congenital hyperinsulinism: 2 case reports with different rare variants in *ABCC8*

Julie Mouron-Hryciuk¹, Sophie Stoppa-Vaucher^{1,2}, Kanetee Busiah¹, Thérèse Bouthors¹, Maria Christina Antoniou¹, Eric Jacot³, Klaus Brusgaard⁴, Henrik Thybo Christesen⁵, Khalid Hussain⁶, Andrew Dwyer⁷, Matthias Roth-Kleiner⁸, Michael Hauschild¹

¹Pediatric Endocrinology and Diabetology Unit, Service of Pediatrics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ²Department of Pediatrics, Hôpitaux Neuchâtelois, Neuchâtel, Switzerland ³Diabetology, Neuchâtel, Switzerland ⁴Department of Clinical Genetics, Odense University Hospital, Odense, Denmark ⁵Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark ⁶Developmental Endocrinology Research Group, Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, UK ⁷Boston College, William F. Connell School of Nursing, Chestnut Hill, MA, USA ⁸Service of Neonatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Received: 18 March 2020
Revised: 9 May 2020
Accepted: 19 May 2020

Address for correspondence:

Michael Hauschild
Pediatric Endocrinology and Diabetology Unit, Service of Pediatrics, Lausanne University Hospital and University of Lausanne, Chemin de Montétan 16 1004 Lausanne, Switzerland
Email: Michael.Hauschild@chuv.ch
<http://orcid.org/0000-0002-1940-8730>

Congenital hyperinsulinism (CHI) is a rare glucose metabolism disorder characterized by unregulated secretion of insulin that leads to hyperinsulinemic hypoglycemia (HH). Most cases are caused by mutations in the K_{ATP} -channel genes *ABCC8* and *KCNJ11*. We report 2 patients that experienced severe HH from the first day of life. Patient 1 developed midgut volvulus after initiating diazoxide and required intestinal resection. He was subsequently managed with a high-dose octreotide and glucose-enriched diet. Consistent with diffuse type CHI by 18F-dihydroxyphenylalanine positron emission tomography-computed tomography, genetic testing revealed a homozygous *ABCC8* variant, c.1801G>A, p.(Val601Ile). The rare variant was previously reported to be diazoxide-responsive, and the patient responded well to diazoxide monotherapy, with clinical remission at 2 years of age. Patient 2 responded to diazoxide with spontaneous clinical remission at 15 months of age. However, an oral glucose tolerance test at 7 years of age revealed hyperinsulinism. Genetic testing revealed that the proband and several seemingly healthy family members harbored a novel, heterozygous *ABCC8* variant, c.1780T>C, p.(Ser594Pro). Genetic findings identified previously unrecognized HH in the proband's mother. The proband's uncle had been diagnosed with monogenic *ABCC8*-diabetes and was successfully transitioned from insulin to glibenclamide therapy. We report findings of intestinal malrotation and volvulus occurring 2 days after initiation of diazoxide treatment. We also report a novel, heterozygous *ABCC8* variant in a family that exhibited cases of CHI in infancy and HH and monogenic diabetes in adult members. The cases demonstrate the importance and clinical utility of genetic analyses for informing and guiding treatment and care.

Keywords: *ABCC8*, Congenital hyperinsulinism, Hypoglycemia, Monogenic diabetes, Midgut volvulus

Highlights

We report 2 patients with CHI caused by novel DNA variants in *ABCC8*. Intestinal malrotation occurred after diazoxide treatment in one patient. Genetic analysis should be performed in all patients and family members that present with CHI to define the best treatment approaches.

Introduction

Congenital hyperinsulinism (CHI) is a rare disease that can result in potentially life-threatening hyperinsulinemic hypoglycemia (HH), caused by inadequate insulin secretion by pancreatic β -cells. The incidence is estimated to be 1:50,000 live births, and 1:2500 live births in communities with founder mutations.¹⁾ Rapid diagnosis and treatment are essential to prevent persistent or recurrent hypoglycemia and neurological damage.²⁻⁵⁾ CHI can be

classified as either transient or permanent and has 3 histologic subtypes: focal, diffuse or atypical CHI. Standard treatment for focal CHI is selective partial pancreatectomy, while diffuse CHI necessitates long-term drug therapy or subtotal pancreatectomy.^{3,6)}

To date, underlying genetic mutations for CHI are identified in 45%–55% of cases. Fourteen genes have been identified (*ABCC8*, *KCNJ11*, *GLUD1*, *GCK*, *HADH*, *HNF1A*, *HNF4A*, *SLC16A1*, *UCP2* and more recently *CACNAID*, *FOXA2*, *HK1*, *PGM1*, and *PMM2*).⁷⁾ That approximately half of the cases do not have an identifiable genetic etiology suggests that additional loci are undiscovered.^{8,9)} Notably, CHI most frequently results from mutations in K_{ATP} -channel genes, *ABCC8* or *KCNJ11*.^{2,3,9,10)} Diazoxide-unresponsive CHI can be caused by homozygous or heterozygous K_{ATP} -channel mutations leading to diffuse CHI. Alternatively, a paternal K_{ATP} -channel mutation and somatic loss of heterozygosity of chromosome 11p15 lead to focal diazoxide-unresponsive CHI. CHI can be nonsyndromic or associated with a range of syndromes, including Beckwith-Wiedemann, Turner, and Kabuki syndrome.¹¹⁾ Novel manifestations in apparently non-syndromic CHI patients can represent a novel syndromic association, unrecognized medical side effects, or chance findings.¹⁰⁾ Notably, spontaneous CHI remission and reversion to diabetes in adulthood have been reported in patients harboring mutations in *ABCC8*, *HNF4A*, or *HNF1A*.¹²⁾ Many patients with monogenic diabetes can be effectively treated with oral antidiabetic medication instead of insulin, which underscores the importance of a genetic diagnosis.¹³⁾

According to recent American College of Medical Genetics guidelines,¹⁴⁾ novel changes should be considered variants of unknown significance (VUS) and should not be considered

pathogenic until the variant is verified in other patients. Accordingly, identifying novel variants associated with reversal of CHI to diabetes in adult life has implications for genetic cascade screening of family members.

We describe 2 patients with novel *ABCC8* mutations associated with spontaneous clinical remission.

Case reports

1. Case 1

A Caucasian male patient was born via normal vaginal delivery at 33^{1/7} weeks gestation to nonconsanguineous parents (Fig. 1A). The pregnancy was unremarkable with no gestational diabetes mellitus. The patient was large-for-gestational age (birthweight, 3,150 g; length, 51 cm; both >97th percentile) with no dysmorphic features. Apgar scores were 5, 8, and 8 (at 1, 5, and 10 minutes, respectively). At 2 hours of life, he developed severe symptomatic hypoglycemia (blood glucose <0.1 mmol/L) with hypotonia. A critical blood sample was drawn, and intravenous (IV) glucose infusion (up to 19 mg/kg/min) was initiated to maintain normoglycemia.

During hypoglycemia, serum insulin, and C-peptide levels were elevated in the setting of suppressed β -hydroxybutyrate and free fatty acids (Table 1). Cortisol, growth hormone, and thyroid hormones were within normal limits, and metabolic and infection screening were negative. Analysis with 18F-dihydroxyphenylalanine positron emission tomography-computed tomography (Discovery 690, GE Healthcare, Chicago, IL, USA) showed general uptake of glucose from the pancreas,




Fig. 1. Pedigrees showing inheritance of *ABCC8* mutations in both families. Squares represent males and circles represent females. The arrow depicts the proband with CHI. The individual IVa of family B underwent genetic testing and was confirmed not to be a carrier of *ABCC8* mutation. (A) Family A: parents (IIIa/b) are asymptomatic carriers. (B) Family B: variable presentation of individuals harboring the heterozygous *ABCC8* mutation, including symptomatic hyperinsulinemic hypoglycemia (IIIb), monogenic diabetes (IIIc), and diabetes of unknown origin (IIId).

Table 1. Clinical and genetic characteristics

| Characteristic | Case 1 | Case 2 | Reference values |
|---|------------------------|------------------------|------------------|
| Age at presentation | 1st day of life | 1st day of life | |
| Clinical signs of CHI | LGA | None | |
| Other signs | Malrotation, volvulus | None | |
| Laboratory results | | | |
| Glucose (mmol/L) | <0.1 | <0.1 | 2.5–6 |
| Insulin (mU/L) | 349.1 | 50.4 | 2.8–13.5 |
| C-peptide (µg/L) | 14.6 | ND | 1.0–3.1 |
| BHB (µmol/L) | <10 | <10 | <400 |
| FFA (mmol/L) | <0.1 | ND | 0.33–0.62 |
| Maximal IV glucose required (mg/kg/min) | 19 | 21 | |
| Diazoxide treatment | | | |
| Dose (mg/kg/day) | 10 | 5 | |
| Duration | 2 Years | 15 Months | |
| Genetic characteristics | | | |
| Location | <i>ABCC8</i> (exon 12) | <i>ABCC8</i> (exon 12) | |
| Mutation type | Missense | Missense | |
| Nucleotide change | c.1801G>A | c.1780T>C | |
| Protein change | p.(Val601Ile) | p.(Ser594Pro) | |
| Inheritance | AR (homozygous) | AD (heterozygous) | |
| <i>In silico</i> prediction | | | |
| PolyPhen-2 | Possibly damaging | Benign | |
| PANTHER | Probably damaging | Probably damaging | |

CHI, congenital hyperinsulinism; LGA, large for gestational age; BHB, beta-hydroxybutyrate; FFA, free fatty acid; IV, intravenous; ND, not described; AR, autosomal recessive; AD, autosomal dominant.




Fig. 2. Axial fluorine-18L-3,4hydroxyphenylalanine positron emission tomography image. Diffuse uptake of F-fluoro-L-DOPA by the pancreas is visualized by the hot spot (white arrow). Physiological distribution of the radiotracer is observed with higher accumulation in the kidneys and lower accumulation in the liver.

suggestive of diffuse CHI (Fig. 2). Oral diazoxide (10 mg/kg/day) was initiated on day 7 of life. Diazoxide combined with high-rate IV glucose infusion (12 mg/kg/min) maintained blood glucose level within normal range. Oral feeding was difficult, and the child developed emesis. Intestinal malrotation, and

volvulus of the ileum were diagnosed on day 9 of life. Diazoxide was discontinued, and 76 cm of necrotic ileum/jejunum was resected with intestinal stoma. Octreotide (up to 48 µg/kg/day subcutaneous, continuously) and amlodipine (0.1 mg/kg/day) were introduced 7 days after surgery, which stabilized blood glucose level with a persistent need for IV glucose in the high-normal range (6–7 mg/kg/min).

Molecular analysis (International Clinical Laboratory of University of Exeter, Exeter, UK) revealed that the proband harbored a homozygous missense DNA variant, c.1801G>A, p.(Val601Ile), in exon 12 of *ABCC8* (reference sequence: NM_001287174.1) (Fig. 3). Amino acids in this residue are evolutionary conserved. Both PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) and PANTHER (<http://pantherdb.org/tools/csnpscoreForm.jsp>) *in silico* algorithms predicted the rare variant to be pathogenic (Table 1).

The unaffected parents were both heterozygous carriers of the *ABCC8* variant. To our knowledge, only 1 case harboring this mutation has been reported.¹⁵ In this report, the *ABCC8* mutation in the male newborn was paternally inherited, and diazoxide was discontinued after 14 months. In the current case, octreotide was weaned after 3 days, and diazoxide treatment was reintroduced followed by a progressive decrease in IV glucose infusion, which was finally stopped at day 54 of life. The intestinal stoma was reversed at 67 days of life with no evidence of short bowel syndrome.

At follow-up at 2 years of life, the patient had no hypoglycemic episodes, and diazoxide was discontinued. A subsequent fasting

tolerance test was age-appropriate, and he exhibited normal growth and neurological development.

2. Case 2

A Hispanic male patient and his healthy, dizygotic twin brother were born via emergency Caesarian section at 34^{4/7} weeks gestation due to abnormal fetal heart rate on cardiotocographic monitoring. The pregnancy was uneventful without gestational diabetes, and no formal glucose tolerance testing was performed. The nonconsanguineous parents had a healthy 3-year-old daughter, and family history revealed several maternal family members with diabetes mellitus (Fig. 1B).

The newborn infant had a birth weight of 2,150 g (50th percentile), while his twin brother weighed 2,550 g. The patient had moderate asphyxia and required noninvasive ventilator support for several days. On his first day of life, he experienced severe hypoglycemia (blood glucose < 0.1 mmol/L) and required IV glucose (up to 21 mg/kg/min) to maintain normoglycemia. Physical examination was unremarkable. The diagnosis of CHI was based on hypoglycemic episodes (< 2.4 mmol/L) on the first day of life, unsuppressed insulin level during hypoglycemia, and high carbohydrate requirements to maintain normal glycemic level (Table 1). Diazoxide treatment promptly resolved the hypoglycemia.

Molecular testing (Odense University Hospital, Odense, Denmark) identified a novel, heterozygous DNA variant, c.1780T>C, p.(Ser594Pro), in exon 12 of *ABCC8* (reference sequence: NM_000352) (Fig. 3). The residue is evolutionarily conserved, and 1 of 2 *in silico* algorithms predicted the variant to be likely deleterious (Table 1). Based on the American College of Medical Genetics guidelines, we considered the change to be a VUS. Diazoxide was discontinued at 15 months of age. Follow-up at 7 years of age revealed normal growth and psychomotor development. He had age-appropriate fasting tolerance without hypoglycemic events. However, a subsequent oral glucose

tolerance test (OGTT) revealed moderate hyperinsulinism (+30 minutes: insulin, 58.8 μ U/L [normal range, 30–50 mU/L]; glucose, 7.7 mmol/L) followed by marginal, nonsymptomatic hypoglycemia at +120 minutes (insulin, 7.37 μ U/L; glucose, 3.1 mmol/L) (Table 2).

Interestingly, the mother (Fig. 1B, IIIb) reported frequent episodes of lightheadedness. Subsequently, an OGTT revealed hyperinsulinism in the mother at +30 minutes (185.5 mU/L) that induced symptomatic HH at +120 minutes (blood glucose, 3 mmol/L; insulin, 27 mU/L) (Table 2). The proband's maternal uncle (Fig. 1B, IIIc) had diabetes mellitus, which was being treated with insulin. Lab testing was negative for antiglutamic acid decarboxylase, anti-insulin, and anti-IA2 antibodies, and serum C-peptide level was 0.68 μ g/L, which was only slightly below the normal range (1.0–3.1 μ g/L). On insulin therapy, the uncle had good metabolic control (glycated hemoglobin) yet suffered frequent hypoglycemic episodes. The maternal great-grandmother (Fig. 1B, Ib) also had been diagnosed with diabetes mellitus, but no detailed clinical information was available.

Cascade screening in the family revealed that the proband's older sister (Fig. 1B, IVa), mother (Fig. 1B, IIIb), maternal uncle (Fig. 1B, IIIc), and maternal grandfather (Fig. 1B, IId) harbored the same heterozygous *ABCC8* variant p.(Ser594Pro). Consequent to genetic testing, the proband's maternal uncle was rediagnosed with monogenic *ABCC8*-diabetes. He was transitioned from insulin to oral antidiabetic medication (glibenclamide 3 \times 5 mg daily) and experienced no further

Table 2. Case 2: Oral glucose tolerance test

| Time (min) | Proband | | Proband's mother | |
|------------|------------------------|----------------------|------------------------|----------------------|
| | Blood glucose (mmol/L) | Insulin (μ U/L) | Blood glucose (mmol/L) | Insulin (μ U/L) |
| 0' | 4.8 | 7.7 | 5.9 | 10.7 |
| 30' | 7.7 | 58.8 | 13.8 | 185.5 |
| 60' | 6.6 | 33.2 | 11.1 | 180.7 |
| 120' | 3.1 | 7.3 | 3 | 50.1 |




Fig. 3. Three-dimensional modelled structure of a pancreatic ATP-sensitive potassium channel. (A) The K_{ATP} channel is a hetero-octameric complex composed of 4 Kir6.2 subunits and 4 SUR1 units. The transmembrane domains are highlighted. (B) The genetic variants in our 2 cases are located on the same transmembrane domain (TMD1) of the SUR1 subunit.

hypoglycemic episodes.

Discussion

We report 2 patients with CHI caused by novel DNA variants in *ABCC8*. Patient 1 was diagnosed with CHI due to a homozygous *ABCC8* mutation inherited from unaffected parents, which was consistent with an autosomal recessive mode of transmission. The patient was unresponsive to diazoxide treatment, and oral intake was not possible. Subtotal pancreatectomy was considered as a potential treatment option; however, a literature review revealed a case of a patient that harbored the identical missense mutation that had responded to diazoxide treatment.¹⁵ Based on the single case observation, we opted to postpone pancreatectomy and use alternative treatment (octreotide and amlodipine) during the postoperative fasting period prior to resuming oral diazoxide. Thus, detailed clinical investigation and scholarly inquiry led to an appropriate clinical approach and avoided irreversible surgical intervention. Cochrane and GRADE criteria consider case reports to be weak levels of evidence. However, for the present case, this information was the best available evidence and helped guide the therapeutic approach.⁶ This example demonstrates how case reports can inform clinical care, particularly in the setting of rare diseases such as CHI.

Intestinal malrotation occurs in approximately 1 in 500 living births. Malrotation is estimated to be symptomatic 1 in 6,000 live births, and up to 80% of symptomatic cases occur in newborns.¹⁶ Risk factors for volvulus include birth defects such as intestinal malrotation, Hirschsprung disease, and isomerism or heterotaxy syndrome. Recently, rare copy number variations (CNVs) have been identified in patients with syndromic intestinal malrotation, suggesting that CNV screening could be informative in cases when intestinal malrotation occurs in a constellation of other malformations.¹⁷ To the best of our knowledge, this is the first report that associated congenital malrotation with neonatal hyperinsulinism. A recent study found 'likely pathogenic' or 'pathogenic' CNVs in 4 of 47 patients (8.5%) with intestinal malrotation.¹⁷ To date, no reports have implicated the 11p15.1 region of *ABCC8* in intestinal malrotation. We are not aware of any study that has identified an association between diazoxide therapy with volvulus, and this possibility merits consideration. It is unclear if co-occurrence of malrotation and CHI is merely a coincidence or if there is a true causal association. Therefore, studies in larger patient cohorts are needed to clarify the potential link between *ABCC8* mutations and midgut malrotation.

Case 2 documents transient CHI due to a heterozygous mutation in *ABCC8*, which is consistent with an autosomal dominant (AD) mode of transmission. A detailed, multigenerational family history and cascade screening facilitated reclassification of the maternal uncle's diabetes mellitus. Patients with monogenic diabetes can be treated with oral antidiabetic medications instead of insulin.¹³ Thus, molecular analysis enabled treatment modification from insulin to oral antidiabetic

medication.

As reported by Kapoor and colleagues, siblings harboring the identical AD mutation in *ABCC8* exhibit variable phenotypes, which can range from asymptomatic macrosomia to persistent HH in childhood to glucose intolerance or early-onset diabetes mellitus in adulthood.¹⁸ Vieira et al.¹⁹ described a patient carrying a *de novo* AD mutation in *ABCC8* in which HH evolved to gestational diabetes and subsequently into diabetes mellitus.

Gain-of-function mutations in *ABCC8* or *KCNJ11* lead to K_{ATP} -channel hyperactivity causing neonatal diabetes. Conversely, loss-of-function mutations that reduce channel activity cause CHI. These observations can be explained by the variable affinity of mutant sulfonylurea receptors for adenosine triphosphate magnesium salt.²⁰ However, it remains unclear how the identical mutation can be associated with disparate phenotypes (i.e., CHI and diabetes) within the same pedigree. Some have hypothesized that the primary insulin secretion defect relates to chronically increased intracellular calcium level that activates apoptotic pathways.¹⁸

In the case in this study, the patient and his unaffected older sister (Fig. 1B, IVa) might have increased risk for developing diabetes mellitus later in life. Accordingly, careful long-term medical follow-up is warranted. The genotype-phenotype correlations in pedigree 2 should be interpreted with caution as other family members with diabetes mellitus did not undergo genetic testing. Although clinical evidence supports the pathogenicity of the identified novel mutation, to-date, *in silico* analyses showed discrepant results, and *in vitro* functional studies of the identified *ABCC8* mutants have not been conducted.

In conclusion, the 2 case reports reported herein illustrate highly variable phenotypes in patients harboring mutations in *ABCC8*. We report a unique finding of intestinal malrotation and volvulus that occurred 2 days after diazoxide treatment in a patient with CHI harboring a homozygous *ABCC8* mutation. Further studies are needed to determine if these entities are pathophysiologically related. The cases demonstrate the importance and clinical utility of genetic analyses for informing and guiding treatment and care. First, only rare cases (case 1) of autosomal recessive, biallelic *ABCC8* mutations are diazoxide-responsive. Second, genetic analysis should be performed in all patients that present with CHI to define the best treatment approaches. Finally, patients with heterozygous mutations in *ABCC8* and their family members should be closely followed clinically, as they might be at increased risk for developing diabetes mellitus.

Ethical statement

The parents have given their written and signed consent for publication of the data of their infants.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

- Bellanné-Chantelot C, Saint-Martin C, Ribeiro MJ, Vaury C, Verkarre V, Arnoux JB, et al. *ABCC8* and *KCNJ11* molecular spectrum of 109 patients with diazoxide-unresponsive congenital hyperinsulinism. *J Med Genet* 2010;47:752-9.
- Kapoor RR, Flanagan SE, Arya VB, Shield JP, Ellard S, Hussain K. Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism. *Eur J Endocrinol* 2013;168:557-64.
- Roženková K, Güemes M, Shah P, Hussain K. The diagnosis and management of hyperinsulinaemic hypoglycaemia. *J Clin Res Pediatr Endocrinol* 2015;7:86-97.
- Helleskov A, Melikyan M, Globa E, Shcherderkina I, Poertner F, Larsen AM, et al. Both low blood glucose and insufficient treatment confer risk of neurodevelopmental impairment in congenital hyperinsulinism: a multinational cohort study. *Front Endocrinol* 2017;8:156.
- Rasmussen AG, Melikyan M, Globa E, Detlefsen S, Rasmussen L, Petersen H, et al. The difficult management of persistent, non-focal congenital hyperinsulinism: a retrospective review from a single, tertiary center. *Pediatr Diabetes* 2020;21:441-55.
- Yorifuji T. Congenital hyperinsulinism: current status and future perspectives. *Ann Pediatr Endocrinol Metab* 2014;19:57-68.
- Gillis D. Familial hyperinsulinism. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al., editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020 [cited 2019 Nov 20]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1375/>.
- Vajravelu ME, De León DD. Genetic characteristics of patients with congenital hyperinsulinism. *Curr Opin Pediatr* 2018;30:568-75.
- Flanagan SE, Kapoor RR, Hussain K. Genetics of congenital hyperinsulinemic hypoglycemia. *Semin Pediatr Surg* 2011;20:13-7.
- Martínez R, Fernández-Ramos C, Vela A, Velayos T, Aguayo A, Urrutia I, et al. Clinical and genetic characterization of congenital hyperinsulinism in Spain. *Eur J Endocrinol* 2016;174:717-26.
- Mohamed Z, Arya VB, Hussain K. Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management. *J Clin Res Pediatr Endocrinol* 2012;4:169-8.
- Rahman SA, Nessa A, Hussain K. Molecular mechanisms of congenital hyperinsulinism. *J Mol Endocrinol* 2015;54:R19-29.
- Misra S, Owen KR. Genetics of monogenic diabetes: present clinical challenges. *Curr Diab Rep* 2018;18:141.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med Off J Am Coll Med Genet* 2015;17:405-24.
- Arya VB, Guemes M, Nessa A, Alam S, Shah P, Gilbert C, et al. Clinical and histological heterogeneity of congenital hyperinsulinism due to paternally inherited heterozygous *ABCC8/KCNJ11* mutations. *Eur J Endocrinol* 2014;171:685-95.
- Strouse PJ. Disorders of intestinal rotation and fixation (« malrotation »). *Pediatr Radiol* 2004;34:837-51.
- Salehi Karlslätt K, Pettersson M, Jäntti N, Szafranski P, Wester T, Husberg B, et al. Rare copy number variants contribute pathogenic alleles in patients with intestinal malrotation. *Mol Genet Genomic Med* 2019;7:e549.
- Kapoor RR, Flanagan SE, James CT, McKiernan J, Thomas AM, Harmer SC, et al. Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant *ABCC8/KCNJ11* mutations. *Diabetologia* 2011;54:2575-83.
- Vieira TC, Bergamin CS, Gurgel LC, Moisés RS. Hyperinsulinemic hypoglycemia evolving to gestational diabetes and diabetes mellitus in a family carrying the inactivating *ABCC8* E1506K mutation. *Pediatr Diabetes* 2010;11:505-8.
- Ortiz D, Bryan J. Neonatal diabetes and congenital hyperinsulinism caused by mutations in *ABCC8/SUR1* are associated with altered and opposite affinities for ATP and ADP. *Front Endocrinol* 2015;6:48.